NEW YORK, Aug. 1, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Menlo Therapeutics Inc. ("Menlo" or the "Company") (NASDAQ: MNLO). Shareholders who purchased Menlo stock in or after the Company's January 2018 initial public offering ("IPO"), are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/mnlo.
The investigation concerns whether Menlo and certain of its officers and/or directors have violated federal securities laws, and specifically focuses on the Company's filings with the U.S. Securities and Exchange Commission in connection with the IPO regarding its second Phase 2 clinical trial of patients treated with serlopitant.
On April 9, 2018, Menlo revealed that Phase 2 clinical trial of serlopitant for the treatment of pruritus in adults and adolescents with a history of atopic dermatitis failed to meet its primary or key secondary efficacy endpoints. The Company also said that the trial did not show a significant difference between patients treated with serlopitant and patients treated with placebo. Following this news, Menlo stock dropped 76.8% to close at $8.17 on April 9, 2018.
If you are aware of any facts relating to this investigation, or purchased Menlo shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/mnlo. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.